RxDoctor Payments Data

Charity Sellers, NP

Family · Kinston, NCNPI 1184183907

Payments from drug & device makers

$969in general payments, 2019–2025

Across 53 payments — averaging $18.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$128
  • Exact Sciences$104
  • Amgen$102
  • GSK$98
  • Corcept Therapeutics$92
  • AbbVie$73
  • plus $371 from 9 others

What the payments were for

  • Food & beverage$969100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$969 in reported general payments places this provider in the 70th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$463
Medicare patients
22
Services billed
50

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide58$77,612
EliquisApixaban60$55,522
Trelegy ElliptaFluticasone/Umeclidin/Vilanter75$50,508
TradjentaLinagliptin39$49,180
FarxigaDapagliflozin Propanediol44$43,749
JardianceEmpagliflozin35$41,076
OzempicSemaglutide38$38,019
MounjaroTirzepatide34$35,752
TrulicityDulaglutide20$28,414
Lantus SolostarInsulin Glargine,hum.Rec.Anlog103$20,650
JanuviaSitagliptin Phosphate16$18,967
XareltoRivaroxaban13$11,921
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr20$9,824
Levemir FlexpenInsulin Detemir24$8,015
Novolog FlexpenInsulin Aspart21$5,259

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$73$77,61258 claims
Lilly USA, LLCMounjaro, Trulicity$33$64,16554 claims
GSKTrelegy Ellipta, Anoro Ellipta$98$60,33295 claims
PfizerEliquis$65$55,52260 claims
AstraZenecaFarxiga, Brilinta$128$48,84256 claims
Novo NordiskOzempic$70$38,01938 claims
MerckJanuvia$62$18,96716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,522 family providers in North Carolina.

Other family in Kinston

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →